NEW YORK (GenomeWeb) – In a filing with the US Securities and Exchange Commission this week, Thermo Fisher Scientific reported it recorded $90 million in restructuring and other costs related to its acquisition of Affymetrix. That expense included $11 million for the sale of inventories revalued at the date of acquisition and to conform the accounting policies of Affymetrix with Thermo Fisher's own accounting policies, and $29 million for third-party transaction costs.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

The Seattle Times writes that pharmacogenomics testing can help choose medications that may work best for people with depression.

Researchers report that deleting one gene from butterflies affects their wing coloration patterns, according to the Washington Post.

In PNAS this week: genome sequencing of weevil symbionts, retinoid X receptor deletion in lung cancer metastasis, and more.

Sequencing could help combat foodborne illnesses, according to a blog post by Food and Drug Administration officials.